AI-extracted from the 10-Q filed 2026-07-30 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
PTC Therapeutics' Q2 2026 revenue of $360.5M more than doubled YoY, driven by Sephience's launch ($151.3M net sales) and a $50.0M Novartis votoplam Phase 3 milestone, while net income was $83.5M.
Biggest Revenue Drivers
Royalty revenue$71.1M+23% YoY
Higher Evrysdi sales compared to the prior-year quarter under the SMA License Agreement.
Collaboration and license revenue$50.6M+over 100% YoY
Primarily a $50.0M development milestone triggered by Novartis's initiation of the first Phase 3 votoplam trial.
Biggest Revenue Drivers
Royalty revenue$71.1M+23% YoY
Higher Evrysdi sales compared to the prior-year quarter under the SMA License Agreement.
Collaboration and license revenue$50.6M+over 100% YoY
Primarily a $50.0M development milestone triggered by Novartis's initiation of the first Phase 3 votoplam trial.
Largest Expense Items
Research and development$99.2M-12% YoY
Decrease primarily from lower development program spend as resources focused on differentiated, high-potential programs.
Selling, general and administrative$80.6M-5% YoY
Decrease primarily due to lower selling expenses related to prelaunch activities for Sephience.
Cost of product, collaboration and license sales (excl. amortization)$19.9M+74% YoY
Driven by higher net product sales, impacting cost of products sold and royalty expense.
Interest expense, net$48.5M+60% YoY
Primarily due to higher non-cash interest expense on the liability for sale of future royalties.
Margins: Income from operations was $149.0M in the quarter versus a $35.0M loss a year earlier, reflecting the revenue ramp; the filing does not provide explicit margin guidance.
Watch Items from the Filing
Translarna revenue declined after the EC adopted the CHMP negative opinion, and the NDA resubmission for Translarna in the US was withdrawn in February 2026.
Three distributors each accounted for over 10% of net product sales in the three months ended June 30, 2026.
Emflaza faces increasing generic competition following expiration of orphan drug exclusivity, negatively affecting its net product revenue.
Issued $550.0M of 0% convertible notes due 2031 and repurchased $222.0M of 2026 notes; $535.4M net proceeds strengthen liquidity, with $1.18B marketable securities on the balance sheet.
Sephience global net sales exceeded $250.0M over four quarters, triggering a $30.0M milestone payable to former Censa securityholders.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
About PTC THERAPEUTICS, INC. (PTCT): stock profile, AI score and financials
PTC THERAPEUTICS, INC. (PTCT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PTCT at 35.9/100 on a composite quality score built from its SEC filings, placing it at rank #2,276 of 2,925 stocks — the bottom half of the AI-ranked universe. Areas of concern include free cash flow (21.4) and earnings quality (21.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 26.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), PTC THERAPEUTICS, INC. reports quarterly revenue of $360.5M, net income of $83.5M, an operating margin of 41.3%. Top institutional holders of PTCT by reported 13-F value include BlackRock, RTW INVESTMENTS, Jupiter Topco, based on the most recent SEC filings. PTCT trades on the Nasdaq exchange and files with the SEC under CIK 1070081. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PTCT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PTC THERAPEUTICS, INC. directly from SEC EDGAR.